According to the latest market report published by Credence Research, Inc. “Urinary Tract Infection (UTI) Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025” the global urinary tract infection (UTI) treatment market was valued at US$ xx Bn in 2016, and is expected to reach US$ xx Bn by 2025, expanding at a CAGR of 3.2% from 2017 to 2025.
Browse the full report Urinary Tract Infection (UTI) Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/urinary-tract-infection-uti-treatment-market
Urinary tract infection (UTI) is a common infections of the urinary tract, which consists of the kidneys, ureters, bladder, urethra or prostate gland. For the purpose of the study UTI treatment market is segmented on the basis of drug type such as penicillin, quinolones, cephalosporin, sulphonamides, tetracycline and other. Among the considered drug type, demand for quinolones is highest in market as these are preferred as first line treatment option. Physician generally prescribe a quinolone medicine if there is no other treatment options existing for a treatment of complicated UTI or kidney infection. In the base year 2016, North America dominated the global UTI treatment market due to large number of target population, higher treatment awareness, swift adoption of novel medications, better reimbursement policies acting as the prime contributors to the dominance of North America. On the other hand, Asia Pacific will show highest UTI treatment market growth during forecast period due to increasing healthcare awareness among general population and growing partnership of key players with local manufacturer.
Market Competition Assessment:
The urinary tract infection (UTI) treatment market is observed to be highly competitive and comprises large number of players. However, some major market players are AstraZeneca plc., Bayer AG, Cubist Pharmaceuticals, F. Hoffmann–La Roche Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Johnson & Johnson, MerLion Pharmaceuticals, Osel Inc., Pfizer Inc., Rempex Pharmaceuticals and other.
To Know More About Assumptions Considered For The Study, Download Report Sample : http://www.credenceresearch.com/sample-request/58749
Key Market Movements:
- Factors such as increase in prevalence of UTI, higher treatment compliance, changing lifestyle pattern and favorable reimbursement policies in some countries are driving the growth of UTI treatment market worldwide.
- Rising access for the treatment medication in developing countries would fuel the growth of UTI treatment market during forecast period.
- However, generic erosion, poor patient compliance in some countries and adverse effects associated with the use of medication is negatively impacting the growth of UTI treatment market.